Voriconazole versus isavuconazole for invasive aspergillosis: a retrospective analysis in a medically insured U.S. population (2017–2020)
VCZ was prescribed five times more frequently than ISA for IA, despite similar treatment durations and completion rates. VCZ was associated with lower costs and did not increase the risk of adverse events or treatment discontinuation. These findings suggest that VCZ remains commonly used and potentially more cost-effective treatment option for IA.
Authors
- Laura Leigh Stoudenmire
- Xianyan Chen (ORCID: https://orcid.org/0000-0002-1806-0883)
- Andres Felipe Henao-Martinez (ORCID: https://orcid.org/0000-0001-7363-8652)
- Daniel B. Chastain (ORCID: https://orcid.org/0000-0002-4018-0195)
- Sophea Chan
- Duna Zhan
Institutions
- Navicent Health (US)
- Georgia College & State University (US)
- University of Georgia (US)
- Phoebe Putney Memorial Hospital (US)
- University of Colorado Anschutz Medical Campus (US)
- Franklin College (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Therapeutic Advances in Infectious Disease
- Published
- 2025-06-27
- DOI
- https://doi.org/10.1177/20499361251347778
- Primary Topic
- Antifungal resistance and susceptibility
- Type
- article
- Field-Weighted Citation Impact
- 0.00